Larimar Therapeutics, Inc. announces that the U.S. Food and Drug Administration has approved them to proceed to a 50 mg cohort in their four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601 in patients with Friedreich's ataxia. In addition, the company’s open label extension trial has been cleared to initiate with participants receiving 25 mg of CTI-1601 daily.